IRIS
RUZZO, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.646
EU - Europa 7.958
AS - Asia 5.628
SA - Sud America 513
Continente sconosciuto - Info sul continente non disponibili 343
AF - Africa 89
OC - Oceania 53
AN - Antartide 2
Totale 29.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.440
CN - Cina 2.718
GB - Regno Unito 2.550
SG - Singapore 1.536
UA - Ucraina 1.208
IT - Italia 987
FR - Francia 685
TR - Turchia 520
SE - Svezia 513
RU - Federazione Russa 494
DE - Germania 490
FI - Finlandia 409
BR - Brasile 399
VN - Vietnam 249
IE - Irlanda 239
PL - Polonia 121
CA - Canada 118
HK - Hong Kong 118
IN - India 110
AT - Austria 79
KR - Corea 58
AU - Australia 47
BD - Bangladesh 45
NL - Olanda 44
JP - Giappone 42
MX - Messico 41
AR - Argentina 34
ID - Indonesia 30
PK - Pakistan 30
BE - Belgio 29
ES - Italia 29
ZA - Sudafrica 29
EC - Ecuador 27
IQ - Iraq 23
SA - Arabia Saudita 22
IR - Iran 17
VE - Venezuela 16
EU - Europa 15
PH - Filippine 13
JO - Giordania 11
TN - Tunisia 11
UZ - Uzbekistan 11
CO - Colombia 10
EG - Egitto 10
AE - Emirati Arabi Uniti 9
RO - Romania 9
BG - Bulgaria 8
LT - Lituania 8
MA - Marocco 8
CL - Cile 7
CR - Costa Rica 7
TG - Togo 7
UY - Uruguay 7
AL - Albania 6
EE - Estonia 6
HN - Honduras 6
KE - Kenya 6
NZ - Nuova Zelanda 6
PE - Perù 6
DO - Repubblica Dominicana 5
DZ - Algeria 5
KG - Kirghizistan 5
MD - Moldavia 5
MY - Malesia 5
PA - Panama 5
TW - Taiwan 5
AM - Armenia 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
GR - Grecia 4
IL - Israele 4
JM - Giamaica 4
LB - Libano 4
LK - Sri Lanka 4
LV - Lettonia 4
NG - Nigeria 4
OM - Oman 4
PY - Paraguay 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BO - Bolivia 3
CH - Svizzera 3
GD - Grenada 3
GT - Guatemala 3
HR - Croazia 3
LU - Lussemburgo 3
MM - Myanmar 3
NI - Nicaragua 3
NP - Nepal 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
CI - Costa d'Avorio 2
CU - Cuba 2
ET - Etiopia 2
GE - Georgia 2
HT - Haiti 2
HU - Ungheria 2
KZ - Kazakistan 2
Totale 28.877
Salva come PNG Salva come JPEG
Città #
Southend 2.274
Fairfield 1.665
Ashburn 1.509
Woodbridge 1.291
Houston 1.170
Jacksonville 964
Singapore 771
Seattle 720
Ann Arbor 679
Cambridge 670
Wilmington 648
San Jose 618
Nanjing 607
Chandler 515
Izmir 400
Beijing 369
Dallas 366
Boardman 271
Dublin 240
Nanchang 215
New York 178
Council Bluffs 169
Helsinki 169
Los Angeles 158
Lauterbourg 151
Princeton 144
Bremen 135
Urbino 124
Hong Kong 111
Shenyang 108
Tianjin 102
San Mateo 101
Kunming 98
Düsseldorf 91
Hebei 90
Kraków 90
Ho Chi Minh City 89
Moscow 84
Santa Clara 80
Jiaxing 73
Istanbul 70
San Diego 69
Changsha 67
Vienna 65
San Francisco 61
Buffalo 60
Chicago 60
Munich 59
Shanghai 58
Hangzhou 56
London 54
Guangzhou 45
São Paulo 45
Hanoi 44
Seongnam 44
The Dalles 44
Velikiy Novgorod 42
Rome 41
Toronto 41
Atlanta 37
Milan 37
Brooklyn 36
Jinan 34
Ancona 30
Tokyo 30
Denver 29
Falls Church 29
Orem 29
Lanzhou 28
Ningbo 27
Phoenix 27
Frankfurt am Main 26
Nuremberg 25
Changchun 24
Warsaw 24
Strasbourg 23
Zhengzhou 23
Brussels 22
Montreal 22
Stockholm 22
Boston 19
Dearborn 19
Rimini 19
Rio de Janeiro 19
Sydney 19
Poplar 18
Riyadh 17
Johannesburg 16
North Bergen 16
Pesaro 16
Augusta 15
Manchester 15
Mülheim 15
Newark 15
Redwood City 15
Taizhou 15
Chennai 14
Mexico City 14
Quito 14
Acton 13
Totale 20.239
Salva come PNG Salva come JPEG
Nome #
2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) 352
C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). 318
XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT 318
TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 317
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients 310
The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome 293
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy 276
KRAS-mutated patients with liver-only metastatic colorectal cancer treated with Bevacizumab and chemotherapy. Functional analysis of TP53 mutations and outcomes 274
Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. 271
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. 269
Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial 268
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC) 268
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 265
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 252
Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). 251
Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer 251
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan 250
Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy 247
VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 245
THE EXPRESSION OF THE KRAS mRNA ISOFORMS 4A AND 4B IN PLASMA: A COMPARISON BETWEEN LUNG ADENOCARCINOMA PATIENTS AND HEALTHY DONORS THROUGH LIQUID BIOPSY 236
Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization 235
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4 234
Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility 233
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition 232
MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC) 231
An erythroid-specific exon is present in the human hexokinase gene 229
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 229
Sex-Related Differences in Impact On Safety Of Pharmacogenetic Profile For Colon Cancer Patients Treated With FOLFOX-4 or XELOX Adjuvant Chemotherapy 226
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC) 225
TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with Ramucirumab-Paclitaxel or standard chemotherapy 225
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer 223
Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region 222
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes 222
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. 222
Glucose metabolism enzymes gene expression analysis and selective metabolism advantage in the clinical progression of colorectal cancer (CRC) 222
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS 222
Hexokinase 221
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma 221
Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington 219
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. 219
High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene. 219
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 219
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients 219
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 218
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 217
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. 215
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 214
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 214
Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy 212
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in italian population 211
The G/A Nucleotide Change at cDNA Position 2494 in the E-Cadherin Gene (CDH1): Analysis in Italian Patients 211
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR 211
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy 209
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer 207
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. 207
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 206
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. 205
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease 204
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 203
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy 200
Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA 200
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer 199
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients. 199
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 199
The genotype of a new linked DNA marker, MP6d-9, is related to the clinicalcourse of cystic fibrosis. 198
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 198
PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL 198
K-RAS STATUS IN PRIMARY COLORECTAL TUMOURS CORRELATE WITH K-RAS STATUS IN RELATED METASTATIC SITES: IMPLICATIONS FOR TREATMENT WITH ANTI-EGFR ANTIBODIES IN CLINICAL SETTING 198
BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 197
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice 196
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? 196
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients 196
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients 196
PTEN EXPRESSION AND KRAS MUTATIONS AS PREDICTORS OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 195
Gender related differences in polymorphism and miRNA targeting CLOCK genes in metastatic colorectal cancer patients 195
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer 195
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district 192
XRCC1 399GG GENOTYPE PREDICTS SIGNIFICANTLY LONGER OVERALL SURVIVAL AND LONG LASTING CR IN RESISTANT LYMPHOMA TREATED WITH BENDA-BEAM AND ASCT 192
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 190
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs 188
Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy 186
[Construction of an apparatus for pulsed field electrophoresis for the analysisof high molecular weight DNA] 184
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial 183
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 183
Glucose-6-phosphate dehydrogenase nucleotide 1311 polymorphism in central Italy(Marche Region). 183
ANALYSIS OF PTEN EXPRESSION AND KRAS MUTATIONS ON PRIMARIES (PRIM) AND METASTASES (METS) TO PREDICT BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 182
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer 181
TS, MTHFR AND XRCC1 GENETIC VARIANTS AFFECT THE CLINICAL COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 180
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patientstreated with surgery and adjuvant chemotherapy. 180
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk italian population 179
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 177
Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts) 176
Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. 176
Structure of the human hexokinase type I gene. 175
Patients treated with FOLFOX-4 or XELOX chemotherapy with high-risk stage II and III colon cancer (TOSCA trial): a different impact of pharmacogenetic profile on toxicity in women and men 175
HOST GENETIC VARIANTS IN THE INSULIN GROWTH FACTOR BINDING PROTEIN-3 IMPACT ON SURVIVAL OF PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH PALLIATIVE CHEMOTHERAPY 174
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 172
Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial 171
Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer 171
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? 169
Totale 21.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.580
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.239 0 0 0 223 82 69 76 95 107 84 81 422
2022/20231.954 286 78 22 201 252 413 7 103 360 70 96 66
2023/2024656 68 52 33 46 82 166 27 45 8 56 7 66
2024/20252.292 116 87 479 147 76 234 282 115 249 216 167 124
2025/20265.451 449 527 637 908 469 366 710 183 405 411 272 114
2026/20271.239 189 170 462 418 0 0 0 0 0 0 0 0
Totale 29.232